Clinical trials: Lenalidomide
Follicular Lymphomas
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
Primary Objective: To compare the complete response rate (CR rate) after induction treatment between the ZR2 regimen and the R2 regimen.<br/><br/>Secondary Objectives: To compare the objective response rate (ORR) after induction…
- Trial name
- NCT07505849
- Testing
- Zanubrutinib+R2, R2
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KeshuZhou
Prostate Cancer
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
The primary objectives of the study are: To evaluate feasibility, safety and tolerance of 6 months administration of Revlimid at 5mg/day and 25mg/day, given orally in subjects with prostate cancer with evidence of biochemical…
- Trial name
- NCT00348595
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma and Plasma Cell Neoplasm
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899080
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Eastern Cooperative Oncology Group
Healthy Volunteers
Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension
This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation.
- Trial name
- NCT02521714
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Non-Hodgkin Lymphoma
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
- Trial name
- NCT03065790
- Testing
- 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
This research study is evaluating the safety and tolerability of the drug lenalidomide in combination with and following mismatched related donor microtransplantation in high risk AML patients in first remission.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia, Acute Myelogenous Leukemia, Acute Granulocytic Leukemia
- Trial name
- NCT02255162
- Testing
- Lenalidomide, HLA-mismatched stem-cell Microtransplantation, Cytarabine
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy
Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males
To find out if the blood level of lenalidomide can be changed when a drug that prevents p-glycoprotein (a protein naturally present in the body that helps carry substances across cell membranes that is found in many parts of the…
- Trial name
- NCT01712828
- Testing
- Lenalidomide, Quinidine, Temsirolimus
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Celgene
High-risk Smoldering Multiple Myeloma, Multiple Myeloma
DARA RVD For High Risk SMM
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and…
- Trial name
- PRISM (NCT04775550)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Omar Nadeem, MD
Myeloma
Maintenance Therapy Using Lenalidomide in Myeloma
Maintenance treatment of myeloma.
- Trial name
- IFM2005-02 (NCT00430365)
- Testing
- lenalidomide
- Where
- 77 sites in Belgium, France and 1 more
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Healthy, Male
Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYP-1512 Tab and Revlimid cap (25mg) when administered a single-dose to healthy male…
- Trial name
- NCT03208218
- Testing
- SYP-1512, Revlimid cap
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Samyang Biopharmaceuticals Corporation
Cognitive Impairment, Mild, Cognitive Dysfunction
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as…
- Conditions
- Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegenerative Disease, Hereditary
- Trial name
- NCT06177028
- Testing
- Lenalidomide 10 mg
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Follicular Lymphoma
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular…
- Trial name
- R2-CHOP2 (NCT01393756)
- Testing
- Lenalidomide and R-CHOP
- Where
- 24 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The Lymphoma Academic Research Organisation
Myeloma Multiple
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
- Trial name
- NCT05091372
- Testing
- Belantamab mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center